BT-20人乳腺癌细胞

价 格:¥3000

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1394

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameBT-20
SynonymsBT 20; BT20
AccessionBTCC-1394
Resource Identification InitiativeTo cite this cell line use: BT-20 (RRID:CVCL_0178)
CommentsGroup: Triple negative breast cancer (TNBC) cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
Part of: GrayJW breast cancer cell line panel.
Part of: ICBP43 breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: PI3K genetic alteration cell panel (ATCC TCP-1028).
Population: Caucasian.
Doubling time: 70 hours (PubMed=25984343); 66.15 hours (GrayJW panel).
Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Breast; UBERON=UBERON_0000310.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635; ATCC).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro539Arg (c.1616C>G); ClinVar=VCV000376243; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351; ATCC).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351; ATCC).
  • Mutation; HGNC; 9884; RB1; Simple; p.Ile388Ser (c.1163T>G); ClinVar=VCV000665312; Zygosity=Homozygous (PubMed=19593635).
  • Mutation; HGNC; 9884; RB1; Simple; p.Pro515Leu (c.1544C>T); Zygosity=Heterozygous (PubMed=19593635).
  • Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Homozygous (PubMed=16541312; PubMed=28889351; ATCC).
HLA typingSource: PubMed=25960936
Class I
HLA-AA*02:01,24:02
HLA-BB*15:01,38:01
HLA-CC*03:03,12:03
Class II
HLA-DQDQB1*06:03,06:03
HLA-DRDRB1*04:05,13:06

Source: PubMed=26589293
Class I
HLA-AA*24:02,24:02
HLA-BB*15:01,67:02
HLA-CC*03:03,12:03
Class II
HLA-DQDQA1*01:02,01:02

DQB1*06:11,06:11
HLA-DRDRB1*04:05,13:01

Source: CLS=300130
Class I
HLA-AA*24:02:01,24:03:01
HLA-BB*15:01:01,14:01:01
HLA-CC*03:03:01,12:03:01
Class II
HLA-DPDPB1*04:01:01G,06:01:01G
HLA-DQDQA1*01:03:01,03:01:01

DQB1*03:02:01,06:03:01
HLA-DRDRB1*04:04:01,13:01:01
Genome ancestrySource: PubMed=30894373

Origin% genome


African5.3
Native American0
East Asian, North9.54
East Asian, South0
South Asian0
European, North43.6
European, South41.56
DiseaseInvasive breast carcinoma of no special type (NCIt: C4194)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:


CVCL_J244 (BT-20/CMV-Luc)CVCL_M061 (BT-20/nKR)
Sex of cellFemale
Age at sampling74Y
CategoryCancer cell line
STR profileSource(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; KCLB; PubMed=25877200; PubMed=28889351

Markers:
AmelogeninX
CSF1PO12
D2S133819
D3S135817
D5S81812
D7S82010
D8S117912
D13S31711
D16S53911 (PubMed=25877200)
11,14 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; PubMed=28889351)
D18S5117
D19S43315
D21S1128,29
FGA22,24
Penta D10,11
Penta E11,13
TH017,9.3
TPOX11
vWA16,17

Run an STR similarity search on this cell line
Web pageshttps://en.wikipedia.org/wiki/BT-20_(cell_line)
https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/BT20.html
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=BT-20
http://www.cells-talk.com/index.php/page/copelibrary?key=BT-20
https://lincs.hms.harvard.edu/resources/reagents/icbp43/
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
Publications

PubMed=13611537; DOI=10.1093/jnci/21.6.1131
Lasfargues E.Y., Ozzello L.
Cultivation of human breast carcinomas.
J. Natl. Cancer Inst. 21:1131-1147(1958)

PubMed=4831449; DOI=10.1093/jnci/52.5.1669
Ozzello L., Sordat B., Merenda C., Carrel S., Hurlimann J., Mach J.-P.
Transplantation of a human mammary carcinoma cell line (BT 20) into nude mice.
J. Natl. Cancer Inst. 52:1669-1672(1974)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

DOI=10.1007/978-1-4757-0019-0_7
Lasfargues E.Y., Coutinho W.G.
Human breast tumor cells in culture; new concepts in mammary carcinogenesis.
(In) New frontiers in mammary pathology; Hollmann K.H., de Brux J., Verley J.M. (eds.); pp.117-143; Plenum Press; New York (1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

DOI=10.1016/B978-0-12-333530-2.50009-5
Leibovitz A.
Cell lines from human breast.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE
Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Am. J. Clin. Pathol. 117:81-89(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

CLPUB00423
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=23151021; DOI=10.1186/1471-2164-13-619
Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619.1-619.14(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050
Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.
The proteomic landscape of triple-negative breast cancer.
Cell Rep. 11:630-644(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers)AddexBio; C0006014/4910
ATCC; CRL-7912 - Discontinued
ATCC; HTB-19
CLS; 300130
IBRC; C10149
KCLB; 60061
NCBI_Iran; C434
Cell line databases/resourcesCLO; CLO_0002041
MCCL; MCC:0000069
CLDB; cl493
CLDB; cl494
CLDB; cl495
cancercelllines; CVCL_0178
CCRID; 1101HUM-PUMC000335
Cell_Model_Passport; SIDM00893
Cosmic-CLP; 906801
DepMap; ACH-000536
IGRhCellID; BT20
LINCS_HMS; 50105
LINCS_LDP; LCL-1476
Lonza; 114
SLKBase; 3481
TOKU-E; 693
Anatomy/cell type resourcesBTO; BTO:0001466
Biological sample resourcesBioSample; SAMN03471671
BioSample; SAMN03472738
BioSample; SAMN10987894
Chemistry resourcesChEMBL-Cells; CHEMBL3307766
ChEMBL-Targets; CHEMBL613870
GDSC; 906801
PharmacoDB; BT20_108_2019
PubChem_Cell_line; CVCL_0178
Encyclopedic resourcesWikidata; Q52392673
Experimental variables resourcesEFO; EFO_0001092
Gene expression databasesArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-TABM-157
GEO; GSM184390
GEO; GSM184391
GEO; GSM350505
GEO; GSM421860
GEO; GSM459725
GEO; GSM783945
GEO; GSM827574
GEO; GSM847197
GEO; GSM847452
GEO; GSM843445
GEO; GSM843446
GEO; GSM886891
GEO; GSM887956
GEO; GSM1053689
GEO; GSM1172940
GEO; GSM1238127
GEO; GSM1374406
GEO; GSM1374407
GEO; GSM1401673
GEO; GSM1669629
Polymorphism and mutation databasesCosmic; 687463
Cosmic; 871137
Cosmic; 904350
Cosmic; 906801
Cosmic; 934519
Cosmic; 979719
Cosmic; 991332
Cosmic; 997914
Cosmic; 1010923
Cosmic; 1017159
Cosmic; 1018465
Cosmic; 1046932
Cosmic; 1047701
Cosmic; 1136370
Cosmic; 1287931
Cosmic; 1289382
Cosmic; 1434946
Cosmic; 1524352
Cosmic; 1603190
Cosmic; 1609471
Cosmic; 1995348
Cosmic; 2009507
Cosmic; 2036672
Cosmic; 2301232
Cosmic; 2301522
Cosmic; 2307195
Cosmic; 2318378
Cosmic; 2361352
IARC_TP53; 3
LiGeA; CCLE_451
Progenetix; CVCL_0178
Proteomic databasesPRIDE; PXD008222
PRIDE; PXD030304
Sequence databasesEGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number44

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部